Phase 6 — Statistical Analysis & Data Interpretation

Phase 6 — Statistical Analysis & Data Interpretation contains 10 topic pages in Pharmacology.

Every assay described in the preceding phases ultimately produces a set of numbers, and the scientific validity of a pharmacological research programme rests as much on the correctness of its statistical analysis as on the quality of its experimental technique. Phase 6 addresses the selection of appropriate statistical tests, the assumptions underlying parametric analysis, dose-response modelling, sample-size and power calculation, and the practical workflow of statistical software such as GraphPad Prism. Biostatistics is the branch of applied statistics concerned specifically with the design, analysis, and interpretation of data arising from biological and health-related research. It differs from general statistics chiefly in its emphasis on the particular data structures and design challenges characteristic of biological experimentation: small sample sizes dictated by ethical and cost constraints, biological variability that is often considerably larger than measurement error, hierarchical or repeated-measures data structures (multiple measurements from the same animal over time), and outcome variables that are frequently non-normally distributed, bounded (such as percentage inhibition), or censored (such as survival time). A firm grounding in biostatistical principles is what allows a pharmacologist to move from a raw dataset to a defensible scientific conclusion, and, conversely, its absence is what most commonly separates a technically well-executed experiment from a publishable, reproducible one. The biostatistical workflow in pharmacological research typically proceeds through four stages: study design (specifying the hypothesis, the experimental units, and the randomisation and blocking scheme, as introduced in Phase 4), data collection (ensuring that the planned statistical analysis is compatible with the data structure actually being generated), data analysis (selecting and correctly applying the appropriate statistical test, the principal focus of the remainder of this phase), and data interpretation (translating a statistical result — a p-value, a confidence interval, an effect size — into a scientifically meaningful conclusion, resisting the common temptation to conflate statistical significance with biological or clinical importance). Statistical analysis is not an optional add-on performed after data collection; it is the scientific foundation that determines whether an observed pharmacological effect reflects a genuine biological phenomenon or is merely the product of random variation. Regulatory agencies including the FDA, EMA, and CDSCO require rigorous, pre-specified statistical analysis for all preclinical data submitted in support of a drug application, and incorrect statistical test selection remains among the most frequent causes of manuscript rejection and, in more serious cases, published-article retraction. The appropriate statistical test is determined jointly by the number of groups being compared, whether the data meet the assumptions of parametric analysis, whether observations are paired or independent, and the nature of the outcome variable itself. For two groups of normally distributed (parametric) data, the independent-samples (unpaired) t-test is appropriate when the two groups consist of different animals or subjects, while the paired t-test is used when the same animals are measured before and after treatment. When more than two groups are compared along a single factor — for example, several dose levels of the same drug — one-way ANOVA followed by an appropriate post-hoc test (Tukey's Honestly Significant Difference test when comparing all groups pairwise, or Dunnett's test when comparing each treatment group only against a single control) is the correct approach. When two factors are varied simultaneously, such as dose and time, two-way ANOVA is required, using a repeated-measures design if the same animals are measured at each time point, with Bonferroni or Šídák correction applied to post-hoc comparisons. When data are non-parametric — small sample size or a distribution that departs from normality — the Mann-Whitney U test is the non-parametric analogue of the unpaired t-test for two independent groups, while the Wilcoxon signed-rank test is the non-parametric analogue for paired data. For more than two non-parametric groups, the Kruskal-Wallis test followed by Dunn's post-hoc test with Bonferroni correction is appropriate. Categorical data, such as proportions or mortality rates, are analysed using the chi-square test, or Fisher's exact test when expected cell frequencies are small. Dose-response relationships (IC50, EC50, LD50) are properly analysed by non-linear regression of the log-transformed dose against response, typically using a four-parameter logistic (4PL) model, described in detail below. Survival data are analysed using Kaplan-Meier curves, compared statistically using the log-rank (Mantel-Cox) test or the Gehan-Breslow-Wilcoxon test, the latter giving greater weight to early events. Finally, the association between two continuous variables is quantified using the Pearson correlation coefficient for parametric data, the Spearman rank correlation for non-parametric data, or Bland-Altman analysis when the goal is to assess agreement between two measurement methods rather than correlation per se. Non-parametric tests make substantially weaker assumptions about the underlying data distribution than their parametric counterparts, analysing the rank order of observations rather than their raw numerical values, and are the appropriate choice whenever the normality or equal-variance assumptions of parametric testing are violated, or whenever sample sizes are too small to assess normality reliably (broadly, fewer than about ten observations per group). Correlation and regression analyses quantify the relationship between two (or more) continuous variables, addressing a fundamentally different scientific question from the group-comparison tests discussed above: not whether groups differ, but how strongly, and in what functional form, two variables are related. Survival analysis encompasses the statistical methods used to analyse time-to-event data — most commonly time to death, but equally applicable to time to relapse, tumour recurrence, or any other clearly defined biological event — and is distinguished from ordinary continuous-data analysis by its ability to correctly handle censored observations, in which the event of interest has not yet occurred (or was not observed) by the end of the study period for some subjects. The Kaplan-Meier method estimates the survival function — the probability of survival beyond a given time point — non-parametrically from the observed event and censoring times, and is conventionally displayed as a step-function survival curve. Comparison of survival curves between two or more treatment groups is performed using the log-rank (Mantel-Cox) test, which weights each observed death equally across the follow-up period, or the Gehan-Breslow-Wilcoxon test, which instead gives greater statistical weight to deaths occurring earlier in the follow-up period and may therefore be more sensitive in studies where a treatment effect is expected to diminish over time. Survival analysis is central to carcinogenicity studies, chronic toxicity studies, and infectious disease models (such as the sepsis and tuberculosis models described in Phase 4), in all of which overall survival is frequently the most clinically and regulatorily meaningful endpoint. A typical Prism-based analysis proceeds through seven stages: importing data in the appropriate table format (XY, Column, or Grouped, depending on the experimental design); generating descriptive statistics, conventionally reported as mean ± SEM; testing normality using the Shapiro-Wilk test; selecting the statistically appropriate test (ANOVA, t-test, or a non-parametric alternative) based on the outcome of the normality assessment; applying the appropriate post-hoc test; where relevant, fitting a dose-response curve using non-linear regression; and finally exporting publication-quality figures, conventionally at a minimum resolution of 300 dpi in TIFF or PDF format. How statistical results are presented is nearly as important as how they are calculated, since a reader or reviewer must be able to independently assess the strength and reliability of the evidence being presented. Continuous data are conventionally presented as mean ± SEM in bar or scatter graphs when the sample size is small, with individual data points overlaid wherever practicable so that the reader can directly assess the underlying data spread rather than relying solely on the summary statistic. Box-and-whisker plots, which display the median, interquartile range, and full data range without assuming a particular distribution, are increasingly preferred for non-parametric or skewed datasets over simple bar-and-error-bar graphs, which can visually misrepresent asymmetric data distributions. Dose-response and time-course data are conventionally presented as XY line or scatter graphs with a fitted regression curve and its 95% confidence band, allowing the reader to assess both the central estimate and its uncertainty at a glance. Figure legends must state, at minimum, the sample size (n) and what it represents (biological versus technical replicates), the summary statistic displayed (mean ± SEM or median ± IQR), the statistical test applied, and the meaning of any significance annotation (asterisks or exact p-values) — omitting any of these elements is a common and easily avoidable source of reviewer criticism. Several recurring statistical errors merit brief mention here, with a comprehensive treatment reserved for the troubleshooting discussion in Phase 7: reporting standard deviation rather than SEM for small samples, running multiple t-tests instead of ANOVA, omitting a post-hoc test following a significant ANOVA, excluding outliers without a pre-specified objective criterion, and applying a parametric test to data that has not been formally assessed for normality. Beyond these mechanical errors, the single most important interpretive principle in pharmacological statistics is that statistical significance (a p-value below the chosen alpha threshold) is not equivalent to biological or clinical importance: a very large sample size can render a trivially small, biologically meaningless difference statistically significant, while a genuinely important biological effect can fail to reach statistical significance in an underpowered study. For this reason, contemporary pharmacological reporting increasingly emphasises effect sizes and their confidence intervals alongside, or in place of, bare p-values, since an effect size directly communicates the magnitude of a finding in a way that a p-value alone cannot. Phase 6 has established the statistical foundation required to interpret pharmacological data correctly: the logic of test selection according to group number, data distribution, and design; the practical assumptions and workflow of parametric testing; the four-parameter logistic model underlying all dose-response analysis; and the mandatory, prospective calculation of sample size. Even the most carefully designed experiment yields misleading conclusions if analysed incorrectly, which is why the pitfalls associated with each stage of this pipeline — including the statistical errors discussed here — are drawn together and addressed systematically in Phase 7.